Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 12/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2907346 | 0.92 | PDE4A (0.49) | PDE4APDE4DPDE4BPDE4CTP53 | |
| SCHEMBL2902044 | 0.91 | PDE4A (0.49) | PDE4APDE4DPDE4BPDE4CTP53 | |
| SCHEMBL2902822 | 0.90 | PDE4A (0.48) | PDE4APDE4DPDE4BPDE4CTP53 | |
| SCHEMBL1157333 | 0.88 | PDE4A (0.56) | PDE4APDE4DPDE4BPDE4CTP53 | |
| SCHEMBL4201212 | 0.87 | PDE4A (0.56) | PDE4APDE4DPDE4BPDE4CTP53 | |
| SCHEMBL4191200 | 0.87 | PDE4A (0.56) | PDE4APDE4DPDE4BPDE4CTP53 | |
| SCHEMBL8285838 | 0.86 | TP53 (0.40) | PDE4APDE4DPDE4BPDE4CTP53 | |
| SCHEMBL4197704 | 0.86 | PDE4A (0.54) | PDE4APDE4DPDE4BPDE4CTP53 | |
| SCHEMBL2902037 | 0.83 | PDE4A (0.46) | PDE4APDE4DPDE4BPDE4CTP53 | |
| SCHEMBL3121037 | 0.83 | PDE4A (0.53) | PDE4APDE4DPDE4BPDE4CLPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007513957-A | — | — | 2007-05-31 | — | — | JP | claimed |
| EP-1692109-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | Memory Pharmaceuticals Corporation (US) | 2006-08-23 | — | — | EP | claimed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | claimed |
| WO-2005061458-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-07-07 | — | — | WO | claimed |
| EP-1692109-B1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARM CORP (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1692109-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | Memory Pharmaceuticals Corporation (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
| WO-2005061458-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | PDE4A, PDE4B, PDE3B | PDE4A 1/4885PDE4D 6/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.